On Monday and Tuesday of this week, CBI's 9th Forum on Patient Reported Outcomes was held in Philadelphia. The expert presenters from pharma, CROs, service providers and academic health centers covered a variety of topics on how to ensure the validity of PRO concepts, patient data and new technologies.
The co-chairs of the event, Ari Gnanasakthy, Executive Director, HE&OR, Novartis, and Susan Vallow, Director for Patient Reported Outcomes at Janssen Global Services, LLC, noted the following emerging themes from the conference as important to the PRO audience in the upcoming months: FDA/EMA regulations; increasing use of PRO in the post-registration environment; how best to use PRO as a quality measure; mixed modality usage and how new collaborative initiatives across the industry are being used to combat inefficiencies in development and how they impact PROs.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.